# NESCIO (NCT05148546)

> Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer

No report yet. It can be ordered.

- Drugs tested: nivolumab; nivolumab plus ipilimumab; nivolumab plus relatlimab
- Indication: resectable clear cell renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05148546
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: The Netherlands Cancer Institute
- Conditions: Renal Cell Carcinoma
- Interventions: Neoadjuvant nivolumab; Neoadjuvant ipilimumab; Neoadjuvant relatlimab
- Enrollment: 69
- Primary outcome: Pathologic response rate

## Questions raised in the commentary

_Automated from the 21 newest of 22 indexed sources (Apr 2022 – Jul 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice._

- How to identify patients most likely to benefit from perioperative immunotherapy
- How neoadjuvant immunotherapy should fit into perioperative treatment
- Which endpoints best capture benefit from neoadjuvant immunotherapy

## Indexed commentary on NESCIO so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 19
- Podcasts: 2
- YouTube: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=nescio-nct05148546

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05148546", "email": "<work email>"}; the inbox owner confirms by the emailed link.